{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Chimérisme : Questions médicales les plus fréquentes",
"headline": "Chimérisme : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Chimérisme : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-04-28",
"dateModified": "2025-04-23",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Chimérisme"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Aberrations des chromosomes",
"url": "https://questionsmedicales.fr/mesh/D002869",
"about": {
"@type": "MedicalCondition",
"name": "Aberrations des chromosomes",
"code": {
"@type": "MedicalCode",
"code": "D002869",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "G05.365.590.175"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Chimérisme",
"alternateName": "Chimerism",
"code": {
"@type": "MedicalCode",
"code": "D046528",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Hui Li",
"url": "https://questionsmedicales.fr/author/Hui%20Li",
"affiliation": {
"@type": "Organization",
"name": "Department of Biochemistry and Molecular Genetics, School of Medicine, University of Virginia, Charlottesville, VA, United States; Department of Pathology, School of Medicine, University of Virginia, Charlottesville, VA, United States. Electronic address: hl9r@virginia.edu."
}
},
{
"@type": "Person",
"name": "Sandeep Singh",
"url": "https://questionsmedicales.fr/author/Sandeep%20Singh",
"affiliation": {
"@type": "Organization",
"name": "Department of Pathology, School of Medicine, University of Virginia, Charlottesville, VA, United States."
}
},
{
"@type": "Person",
"name": "Hao Zhang",
"url": "https://questionsmedicales.fr/author/Hao%20Zhang",
"affiliation": {
"@type": "Organization",
"name": "Institute of Precision Cancer Medicine and Pathology, Jinan University Medical College, Guangzhou, Guangdong, China. haozhang@jnu.edu.cn."
}
},
{
"@type": "Person",
"name": "Xinrui Shi",
"url": "https://questionsmedicales.fr/author/Xinrui%20Shi",
"affiliation": {
"@type": "Organization",
"name": "Department of Biochemistry and Molecular Genetics, School of Medicine, University of Virginia, Charlottesville, VA, United States."
}
},
{
"@type": "Person",
"name": "Yusheng Lin",
"url": "https://questionsmedicales.fr/author/Yusheng%20Lin",
"affiliation": {
"@type": "Organization",
"name": "Institute of Precision Cancer Medicine and Pathology, Jinan University Medical College, Guangzhou, Guangdong, China."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Does Non-Classic Lobular Carcinoma In Situ at the Lumpectomy Margin Increase Local Recurrence?",
"datePublished": "2023-07-26",
"url": "https://questionsmedicales.fr/article/37493892",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1245/s10434-023-13899-1"
}
},
{
"@type": "ScholarlyArticle",
"name": "Salvage Cryoablation for Local Recurrences of Thyroid Cancer Inseparable from the Trachea and Neurovascular Structures.",
"datePublished": "2022-10-08",
"url": "https://questionsmedicales.fr/article/36220608",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jvir.2022.10.001"
}
},
{
"@type": "ScholarlyArticle",
"name": "Predictors of recurrence following local excision for early-stage anal squamous cell carcinoma.",
"datePublished": "2023-09-22",
"url": "https://questionsmedicales.fr/article/37801832",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ejso.2023.107093"
}
},
{
"@type": "ScholarlyArticle",
"name": "Predictors, Patterns, and Timing of Recurrence Provide Insight into the Disease Biology of Invasive Carcinomas Arising in Association with Intraductal Papillary Mucinous Neoplasms.",
"datePublished": "2022-08-01",
"url": "https://questionsmedicales.fr/article/35915375",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s11605-022-05428-4"
}
},
{
"@type": "ScholarlyArticle",
"name": "Distance between tumor and bronchial resection margin is an independent predictor of recurrence-free survival and overall survival in primary endobronchial neoplasm.",
"datePublished": "2023-06-23",
"url": "https://questionsmedicales.fr/article/37351623",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00432-023-04917-6"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Phénomènes génétiques",
"item": "https://questionsmedicales.fr/mesh/D055614"
},
{
"@type": "ListItem",
"position": 3,
"name": "Variation génétique",
"item": "https://questionsmedicales.fr/mesh/D014644"
},
{
"@type": "ListItem",
"position": 4,
"name": "Mutation",
"item": "https://questionsmedicales.fr/mesh/D009154"
},
{
"@type": "ListItem",
"position": 5,
"name": "Aberrations des chromosomes",
"item": "https://questionsmedicales.fr/mesh/D002869"
},
{
"@type": "ListItem",
"position": 6,
"name": "Chimérisme",
"item": "https://questionsmedicales.fr/mesh/D046528"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Chimérisme - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Chimérisme",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-02",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Chimérisme",
"description": "Comment diagnostiquer le chimérisme ?\nQuels tests sont utilisés pour le chimérisme ?\nLe chimérisme peut-il être détecté par échographie ?\nQuels signes cliniques peuvent indiquer un chimérisme ?\nLe chimérisme est-il héréditaire ?",
"url": "https://questionsmedicales.fr/mesh/D046528?mesh_terms=Neoplasm+Recurrence,+Local&page=6#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Chimérisme",
"description": "Quels sont les symptômes du chimérisme ?\nLe chimérisme cause-t-il des douleurs ?\nPeut-on avoir des symptômes sans chimérisme ?\nLe chimérisme affecte-t-il la croissance ?\nY a-t-il des symptômes spécifiques au chimérisme ?",
"url": "https://questionsmedicales.fr/mesh/D046528?mesh_terms=Neoplasm+Recurrence,+Local&page=6#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Chimérisme",
"description": "Peut-on prévenir le chimérisme ?\nY a-t-il des facteurs de risque pour le chimérisme ?\nLes tests prénataux peuvent-ils détecter le chimérisme ?\nLe chimérisme est-il lié à des pratiques médicales ?\nLes femmes enceintes doivent-elles se méfier du chimérisme ?",
"url": "https://questionsmedicales.fr/mesh/D046528?mesh_terms=Neoplasm+Recurrence,+Local&page=6#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Chimérisme",
"description": "Comment traiter le chimérisme ?\nLe chimérisme nécessite-t-il une intervention chirurgicale ?\nLes médicaments peuvent-ils aider au chimérisme ?\nY a-t-il des traitements naturels pour le chimérisme ?\nLe suivi médical est-il nécessaire pour le chimérisme ?",
"url": "https://questionsmedicales.fr/mesh/D046528?mesh_terms=Neoplasm+Recurrence,+Local&page=6#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Chimérisme",
"description": "Quelles complications peuvent survenir avec le chimérisme ?\nLe chimérisme peut-il causer des cancers ?\nComment gérer les complications du chimérisme ?\nLe chimérisme affecte-t-il le système immunitaire ?\nY a-t-il des risques de rejet avec le chimérisme ?",
"url": "https://questionsmedicales.fr/mesh/D046528?mesh_terms=Neoplasm+Recurrence,+Local&page=6#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Chimérisme",
"description": "Quels sont les facteurs de risque du chimérisme ?\nLe chimérisme est-il plus fréquent chez certaines populations ?\nLes greffes augmentent-elles le risque de chimérisme ?\nLes antécédents médicaux influencent-ils le chimérisme ?\nLe chimérisme est-il lié à des facteurs environnementaux ?",
"url": "https://questionsmedicales.fr/mesh/D046528?mesh_terms=Neoplasm+Recurrence,+Local&page=6#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer le chimérisme ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic se fait par analyse génétique, notamment par PCR ou séquençage."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour le chimérisme ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests incluent l'analyse de l'ADN, les tests de compatibilité tissulaire et les marqueurs génétiques."
}
},
{
"@type": "Question",
"name": "Le chimérisme peut-il être détecté par échographie ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, l'échographie ne peut pas détecter le chimérisme, seul un test génétique est fiable."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques peuvent indiquer un chimérisme ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes cliniques peuvent inclure des anomalies immunitaires ou des différences phénotypiques."
}
},
{
"@type": "Question",
"name": "Le chimérisme est-il héréditaire ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, le chimérisme n'est généralement pas héréditaire, il résulte d'événements embryonnaires."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes du chimérisme ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes varient, mais peuvent inclure des anomalies cutanées ou des troubles immunitaires."
}
},
{
"@type": "Question",
"name": "Le chimérisme cause-t-il des douleurs ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le chimérisme en soi ne cause pas de douleurs, mais des complications peuvent en entraîner."
}
},
{
"@type": "Question",
"name": "Peut-on avoir des symptômes sans chimérisme ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, de nombreux symptômes peuvent être causés par d'autres conditions médicales."
}
},
{
"@type": "Question",
"name": "Le chimérisme affecte-t-il la croissance ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il peut affecter la croissance si des anomalies génétiques ou hormonales sont présentes."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes spécifiques au chimérisme ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des différences de pigmentation ou des anomalies immunitaires peuvent être spécifiques."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir le chimérisme ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le chimérisme ne peut pas être prévenu car il résulte d'événements embryonnaires."
}
},
{
"@type": "Question",
"name": "Y a-t-il des facteurs de risque pour le chimérisme ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs de risque incluent des grossesses multiples ou des transfusions sanguines."
}
},
{
"@type": "Question",
"name": "Les tests prénataux peuvent-ils détecter le chimérisme ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests prénataux standard ne détectent pas le chimérisme, des tests génétiques spécifiques sont nécessaires."
}
},
{
"@type": "Question",
"name": "Le chimérisme est-il lié à des pratiques médicales ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines pratiques comme les greffes peuvent augmenter le risque de chimérisme."
}
},
{
"@type": "Question",
"name": "Les femmes enceintes doivent-elles se méfier du chimérisme ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'y a pas de mesures préventives spécifiques pour les femmes enceintes concernant le chimérisme."
}
},
{
"@type": "Question",
"name": "Comment traiter le chimérisme ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement dépend des symptômes et peut inclure des thérapies immunosuppressives."
}
},
{
"@type": "Question",
"name": "Le chimérisme nécessite-t-il une intervention chirurgicale ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Rarement, sauf si des complications graves nécessitent une intervention spécifique."
}
},
{
"@type": "Question",
"name": "Les médicaments peuvent-ils aider au chimérisme ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des médicaments immunosuppresseurs peuvent être prescrits pour gérer les symptômes."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements naturels pour le chimérisme ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de traitements naturels prouvés pour le chimérisme, consultez un médecin."
}
},
{
"@type": "Question",
"name": "Le suivi médical est-il nécessaire pour le chimérisme ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un suivi régulier est essentiel pour surveiller les complications potentielles."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec le chimérisme ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des troubles immunitaires, des rejets de greffe ou des cancers."
}
},
{
"@type": "Question",
"name": "Le chimérisme peut-il causer des cancers ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines formes de chimérisme peuvent augmenter le risque de cancers spécifiques."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications du chimérisme ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion implique un suivi médical régulier et des traitements adaptés aux symptômes."
}
},
{
"@type": "Question",
"name": "Le chimérisme affecte-t-il le système immunitaire ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le chimérisme peut entraîner des dysfonctionnements du système immunitaire."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de rejet avec le chimérisme ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le rejet peut survenir si des cellules étrangères sont reconnues par le système immunitaire."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque du chimérisme ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les grossesses multiples et les transfusions sanguines sont des facteurs de risque connus."
}
},
{
"@type": "Question",
"name": "Le chimérisme est-il plus fréquent chez certaines populations ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'y a pas de données précises, mais les grossesses multiples peuvent augmenter le risque."
}
},
{
"@type": "Question",
"name": "Les greffes augmentent-elles le risque de chimérisme ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les greffes d'organes peuvent introduire des cellules étrangères, entraînant un chimérisme."
}
},
{
"@type": "Question",
"name": "Les antécédents médicaux influencent-ils le chimérisme ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents de transfusions ou de greffes peuvent augmenter le risque de chimérisme."
}
},
{
"@type": "Question",
"name": "Le chimérisme est-il lié à des facteurs environnementaux ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de preuves solides liant le chimérisme à des facteurs environnementaux."
}
}
]
}
]
}
The clinical significance of nonclassic, lobular carcinoma in situ (NC-LCIS) at the surgical margin of excisions for invasive cancer is unknown. We sought to determine whether NC-LCIS at or near the m...
Patients with stage 0-III breast cancer and NC-LCIS who underwent lumpectomy between January 2010 and January 2022 at a single institution were retrospectively identified. NC-LCIS margins were stratif...
A total of 511 female patients (median age 60 years [interquartile range (IQR) 52-69]) with NC-LCIS and an associated ipsilateral breast cancer with a median follow-up of 3.4 years (IQR 2.0-5.9) were ...
For completely excised invasive breast cancers associated with NC-LCIS, extent of margin width for NC-LCIS was not associated with a difference in IBTR or LRR. These data suggest that the decision to ...
To demonstrate safety, feasibility, and effectiveness of cryoablation of recurrent papillary thyroid cancer ineligible for reoperation because of scarring, eligible for focal ablation as defined withi...
With multidisciplinary consensus, cryoablation was performed with curative intent for 15 tumors in 10 patients between January 2019 and July 2021. Demographics, procedural details, and serial postproc...
The mean age was 72.5 years (range, 57-88 years), and 80% of the patients were women. The tumors (mean size, 16 mm ± 6; range, 9-29 mm) received 1 session of cryoablation with 100% technical success. ...
Cryoablation of local recurrences of papillary thyroid cancer abutting the trachea and/or neurovascular structures in the setting of hydrodissection failure because of scarring yielded a mean volumetr...
There is increasing use of local excision (LE) for definitive treatment of early-stage anal squamous cell carcinoma (ASCC) to avoid the morbidity associated with chemoradiotherapy (CRT). However, the ...
A detailed analysis of patient characteristics, histology results, recurrence patterns and salvage treatment was conducted in consecutive T1/T2N0 ASCC patients treated by LE 2010-2021 across a UK regi...
Of 621 ASCC patients discussed in the network MDT, 164 had early-stage disease (T1/T2 N0). Of these, 36 (22%) were deemed suitable for LE (median age 61 years, female to male ratio 2:1). Twenty-two LE...
LE for T1/T2 N0 ASCC of the margin or canal is a viable treatment strategy to avoid the morbidity associated with CRT and salvage treatments are still available for patients that develop recurrence. T...
To identify predictors, patterns, and timing of recurrence after resection of invasive carcinomas arising in association with an IPMN....
Postoperative management of an invasive carcinoma arising in association with an intraductal papillary mucinous neoplasm (IPMN), a biologically distinct entity from PanIN-derived pancreatic ductal ade...
Patients were identified from a prospectively maintained registry between 1996 and 2018. Predictors of recurrence were evaluated by employing Cox regression models to determine risk-adjusted hazard ra...
Of the 213 patients included, 92 (43.2%) recurred with a median RFS of 23.7 months (16.7-30.7). The predominant pattern of recurrence included any systemic (65.2%). The median time to local recurrence...
The predominant pattern of recurrence after resection of invasive carcinomas arising in association with IPMNs is systemic, and occurs earlier than local recurrence. Poor differentiation and nodal dis...
The distance between tumor and bronchial resection margin (DBTM) had no clear standard in lung cancer surgery. We aimed to select the optimal cut-off value to provide a standard for surgery of the pat...
We retrospectively analyzed patients with primary endobronchial neoplasm who underwent surgical resection between 2005 and 2012. The receiver operating characteristic curves and the Youden index were ...
A total of 1048 patients comprised in the study cohort and 1.7 cm was determined the optimal cut-off value, including 531 grouped in DBTM ≤ 1.7 cm and 517 grouped in DBTM > 1.7 cm. Before propensity s...
The DBTM was an independent predictor for outcomes in primary endobronchial neoplasm, and patients with the DBTM ≤ 1.7 cm should actively receive adjuvant therapy after surgery. The distance between t...
We report our long-term experience with high dose rate intraoperative radiotherapy (HDR-IORT) in a single, quaternary institution....
From 2004 to 2020, 60 HDR-IORT procedures for locally advanced colorectal cancer (LACC) and 81 for locally recurrent colorectal cancer (LRCC) were done in our institution. Preoperative radiotherapy wa...
With a median follow-up time of 4 years, 3-, 5-, and 7- year, overall survival (OS) rates were 84%, 58%, and 58% for LACC and 68%, 41%, and 37% for LRCC, respectively. Local progression-free survival ...
Favorable OS and LPFS can be achieved for LACC and LRCC with intensive local therapy. In patients with risk factors for poorer outcomes, optimization of EBRT and IORT, surgical resection, and systemic...
Assess multiparametric-MRI (mp-MRI) diagnostic accuracy in the detection of local recurrence of Prostate Cancer (PCa) after Radical Prostatectomy (PR) and before Radiation Therapy (RT)....
A total of 188 patients underwent 1.5-T mp-MRI after RP before RT. Patients were divided into two groups: with biochemical recurrence (group A) and without but with high risk of local recurrence (grou...
PCa recurrence (reduction of PSA levels after RT) was 89.8% in the group A and 80.3% in the group B. Comparing patients with and without PCa recurrence, there was a significant difference in PSA value...
mp-MRI should always be performed before RT when a recurrence is suspected. New scenarios can be opened considering the role of DWI for PSA ≤ 0.5 ng/ml....
To evaluate the safety, and short to mid-term oncological and quality-of-life (QoL) outcomes of focal irreversible electroporation (IRE) for radio-recurrent prostate cancer (PCa) at a median follow-up...
This was a single-centre series of men with biopsy-proven radio-recurrent PCa treated with IRE between December 2013 and February 2022, with a minimum follow-up of 6 months. Follow-up included magneti...
Final analysis was performed on 74 men with radio-recurrent PCa (median age 69 years, median PSA level 5.4 ng/mL, 76% ISUP score 2/3). The median (range) follow-up was 48 (27-68) months. One rectal fi...
These short- to mid-term safety, oncological and QoL outcome data endorse results from smaller series and show the ability of salvage focal IRE to safely achieve oncological control in patients with r...
Photoimmunotherapy for head and neck cancer (HNC-PIT) is a newly developed locoregional treatment targeting the epidermal growth factor. This treatment consists in administering cetuximab sarotalocan ...
The adequate surgical margin for local control of buccal mucosa squamous cell carcinoma (BMSCC) is under debate. This study investigates surgical margins and other factors associated with local recurr...
Multiple factors were evaluated retrospectively in 97 patients with BMSCC. Cox-regression and Kaplan-Meier curves were used for analysis....
The local recurrence rate was 23%. The tumor-free margin was <5.0 mm in 89% of the patients and the deep margin was significantly more often inadequate. Multivariate analysis associated pT3-classifica...
Adequate tumor-free margins are pivotal for LRFS of BMSCC. PO(ch)RT, not re-resection, can improve LRFS in patients with <5.0 mm tumor-free margins....
